Clinical trial
A Phase 2 Study of Ataluren (PTC124®) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia
NCT01141075 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Ataluren (PTC124®) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 19, 2010
- Completion date
- November 3, 2011
- Enrollment
- 11 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.